Trials / Completed
CompletedNCT02345408
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
Detailed description
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCX872-B | Tablets (oral administration) |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2020-05-06
- Completion
- 2020-05-06
- First posted
- 2015-01-26
- Last updated
- 2025-02-27
Locations
6 sites across 2 countries: United States, Netherlands
Source: ClinicalTrials.gov record NCT02345408. Inclusion in this directory is not an endorsement.